Table 1.
Patients Characteristics According to CHIP-AM Mutation.
| CHIP-AM | No-CHIP | Total | P | |
|---|---|---|---|---|
| n = 51 | n = 26 | n = 77 | ||
| First cancer, n (%) | 0.1a | |||
| Breast cancer | 33 (65%) | 21 (81%) | 54 (70%) | |
| Gynecological cancer | 18 (35%) | 5 (19%) | 23 (30%) | |
| First cancer treatment, n (%) | 0.2a | |||
| Chemotherapy/radiotherapy | 36 (71%) | 16 (62%) | 52 (68%) | |
| Radiotherapy alone | 4 (8%) | 6 (23%) | 10 (13%) | |
| Chemotherapy alone | 11 (22%) | 4 (15%) | 15 (19%) | |
| Number of treatment lines, mean (SD) | 2.33 (1.97) | 1.65 (1.09) | 2.1 (1.74) | 0.2b |
| Alkylating agent, n (%) | 42 (82%) | 21 (81%) | 63 (82%) | 0.9a |
| Anthracycline, n (%) | 29 (57%) | 20 (77%) | 49 (64%) | 0.08a |
| Median time between TRMN | 6.6 (3–13.2) | 2.9 (2–4.8) | 5.1 (3.6–6.6) | <0.001c |
| and cancer, y (95% CI) | ||||
| Median age at TRMN, y (IQR) | 64 (56–72.5) | 56 (49.25–65.75) | 62 (54–70) | 0.022b |
| Performance status, n (%) | 0.6a | |||
| 0–1 | 36 (71%) | 20 (77%) | 56 (73%) | |
| 2–3 | 15 (29%) | 6 (23%) | 21 (27%) | |
| Myeloid neoplasm, n (%) | 0.2a | |||
| AML | 30 (59%) | 19 (73%) | 49 (64%) | |
| MDS | 21 (41%) | 7 (27%) | 28 (36%) | |
| Cytogenetic failure, n (%) | 3 (6%) | 1 (4%) | 4 (5%) | >0.99d |
| Normal karyotype, n (%) | 9 (18%) | 6 (23%) | 15 (21%) | >0.99a |
| Balanced translocation, n (%) | 6 (12%) | 13 (50%) | 19 (25%) | <0.001a |
| Complex karyotype, n (%) | 24 (47%) | 1 (4%) | 25 (34%) | <0.001a |
| Gene mutations, mean (SD) | 2.67 (1.53) | 1.42(1.17) | 2.25 (1.53) | <0.001b |
| ELN 2017 AML classification, n (%) | 0.009a | |||
| Adverse | 18 (60%) | 3 (16%) | 21 (43%) | |
| Favorable | 7 (23%) | 8 (42%) | 15 (31%) | |
| Intermediate | 5 (17%) | 8 (42%) | 13 (27%) | |
| MDS IPSS score, n (%) | 0.038d | |||
| Low/Int1 | 1 (5%) | 3 (43%) | 4 (14%) | |
| Int2/high | 20 (95%) | 4 (57%) | 24 (86%) | |
| TRMN treatment, n (%) | 0.2a | |||
| Intensive | 19 (37%) | 15 (58%) | 34 (44%) | |
| Low dose | 20 (39%) | 7 (27%) | 27 (35%) | |
| BSC | 12 (24%) | 4 (15%) | 16 (21%) | |
| CR rate, n (%) | 25 (49%) | 17 (65%) | 42 (55%) | 0.2a |
| HSCT, n (%) | 10 (20%) | 6 (23%) | 16 (21%) | 0.7a |
| Median OS, mo (95% CI) | 14.3 (8.7–23) | 12.8 (8.6–NR) | 13.9 (10.5–20.4) | 0.4c |
| Median EFS, mo (95% CI) | 9.6 (6.1–17) | 10.6 (5.7–34.6) | 10.1 (6.8–16.3) | 0.4c |
aPearson's Chi-square test.
bWilcoxon test.
cLogrank test.
dFisher's exact test.
AML = acute myeloid leukemia; BSC = best supportive care; CHIP-AM = CHIP-associated mutations; CI = confidence interval; CR = complete remission; EFS = event-free survival; HSCT = hematopoietic stem cell transplantation; IQR = intervalle quartile range; MDS = myelodysplastic syndrome; NR = not reached; OS = overall survival; TRMN = therapy-related myeloid neoplasm.